SOUTH SAN FRANCISCO, Calif., June 16, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list, based on an employee survey of Bay Area companies.
"We truly believe that our employees are our best asset and are honored to be recognized by the Bay Area News Group as a Top Workplace," said Bonnie H. Anderson, president and chief executive officer of Veracyte. "At Veracyte, we value creative, critical, focused thinkers who are driven by our goal of improving patient care, and we are dedicated to a culture that enables each employee to make meaningful contributions to our success. This award validates that our approach is working."
The Bay Area News Group, which owns the San Jose Mercury News, Oakland Tribune, Contra Costa Times and other media properties, ranked Veracyte as one of the top small businesses to work for in the Bay Area on its 2014 list. The Top Workplaces are determined based solely on employee feedback. The employee survey is conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement. WorkplaceDynamics conducts regional Top Workplaces programs with 40 major publishing partners across the United States. Veracyte was selected based on the survey results measuring employee engagement, organizational health, satisfaction and company culture.
The Bay Area News Group published the complete list of Top Workplaces on Sunday, June 15. The list of winners is available on the San Jose Mercury News website.
This marks the latest recognition honoring Veracyte's leadership and accomplishments. Previously, the company was named to the Wall Street Journal's "Next Best Thing" list and was honored with FierceMedicalDevice's "Fierce 15" award. Ms. Anderson was also named one of the "Best Bay Area Life Sciences CEOs" by the San Francisco Business Times.
About Veracyte, Inc.
Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, provides a comprehensive approach for assessing thyroid nodules, centered on the proprietary Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis. Each year, of the more than 525,000 thyroid nodule FNAs performed
in the U.S., approximately 115,000 patients undergo diagnostic thyroid surgery, with 70% to 80% of nodules proving benign and thus the surgery unnecessary. Veracyte commercially launched Afirma in January 2011. As of March 31, 2014, the company has received nearly 100,000 FNA samples for evaluation using Afirma and has performed nearly 20,000 GECs to resolve indeterminate cytopathology results. Backed by multiple, peer-reviewed, published studies and included in leading medical guidelines, Afirma is covered by Medicare and major commercial payers, which collectively represent more than 125 million covered lives. Afirma is marketed and sold through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi. Veracyte
intends to expand its molecular cytology franchise to other clinical areas and is in late biomarker discovery for its first product in pulmonology. For more information, please visit www.veracyte.com.
Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.
Media:
Tracy Morris
650-380-4413
Tracy.Morris@Veracyte.com
SOURCE Veracyte